CYP19A1 and breast carcinoma: Estrogen-induced expression of peptides growth factors is the major concern in the development and growth of estrogen-responsive mammary cancer: inhibition of this circuitry is the rationale for the use of antiestrogens and aromatase inhibitors to treat these types of breast cancer [90,91].